重组人干扰素α2b阴道泡腾胶囊治疗宫颈人乳头瘤病毒感染的临床研究

Recombinant human interferon α2b vaginal effervescent capsules in the treatment of patients with human papilloma virus infection

目的评价重组人干扰素α2b阴道泡腾胶囊对宫颈人乳头瘤病毒(HPV)感染的疗效。方法 128例宫颈HPV感染患者随机分为试验组(62例)和对照组(66例)。试验组患者于末次月经干净3 d后,在阴道内放置重组人干扰素α2b阴道泡腾胶囊,每晚1粒,10 d为1个疗程,持续3个疗程。对照组患者予以定期随访观察,未做处理。3个疗程后,比较2组宫颈HPV阴转率、宫颈糜烂程度及不良反应。结果 3个疗程后,试验组HPV-DNA转阴48例,阴转率为77.4%,对照组HPV-DNA自行转阴4例,阴转率为6.1%,试验组阴转率显著高于对照组(P<0.05);试验组宫颈糜烂面积缩小者30例,有效率为63.8%(30/47),对照组宫颈糜烂面积缩小者4例,有效率为8.3%(4/48),试验组有效率显著高于对照组(P<0.05)。试验组患者无明显不良反应发生。结论重组人干扰素α2b阴道泡腾胶囊对宫颈HPV感染疗效显著,同时可减轻患者宫颈糜烂程度。

Objective To evaluate the clinical efficacy of recombinant human interferon α2b vaginal effervescent capsules on patients with human papilloma virus（ HPV） infection. Methods One hundred and twenty- eight patients with HPV infection were recruited in this prospective study from October 2011 to October 2013 and randomly divided into the treatment group（ n = 62） and the control group（ n = 66）. Patients in the treatment group were given one human interferon α2b vaginal effervescent capsule per day. The treatment lasted for 3 cycles（ 10 days as a cycle）. Patients in the control group were followed up and observed.After 3- month treatment,the data of HPV infection rate,cervical erosion and side effects in two group were compared. Results After treatment,forty- eight cases in the treatment group became HPV negative（ 77. 4%） and 4 cases become HPV negative（ 6. 1%） in control group,which showed the negative rate in the treatment group was much higher than that in the control group（ P〈0. 05）; the effective rates on cervical erosion were 63. 8%（ 30 /47） and 8. 3%（ 4 /48） respectively in treatment group and control group（ P〈0. 05）. There were no significant adverse reactions found in the treatment group. Conclusion The recombinant human interferon α2b vaginal effervescent capsule for the treatment of HPV infection is significantly effective, relieving the seriousness of cervical erosion as well.